Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Neurobiology of Disease
Steven S Plotkin, Neil R Cashman

Abstract

Amyloid-β (Aβ) and tau proteins currently represent the two most promising targets to treat Alzheimer's disease. The most extensively developed method to treat the pathologic forms of these proteins is through the administration of exogenous antibodies, or passive immunotherapy. In this review, we discuss the molecular-level strategies that researchers are using to design an effective therapeutic antibody, given the challenges in treating this disease. These challenges include selectively targeting a protein that has misfolded or is pathological rather than the more abundant, healthy protein, designing strategic constructs for immunizing an animal to raise an antibody that has the appropriate conformational selectivity to achieve this end, and clearing the pathological protein species before prion-like cell-to-cell spread of misfolded protein has irreparably damaged neurons, without invoking damaging inflammatory responses in the brain that naturally arise when the innate immune system is clearing foreign agents. The various solutions to these problems in current clinical trials will be discussed.

Citations

Dec 18, 2020·Frontiers in Neurology·Maria MasnataFrancesca Cicchetti
Mar 16, 2021·Frontiers in Aging Neuroscience·Allal BoutajangoutThomas Wisniewski
Mar 14, 2021·Acta Neuropathologica Communications·Rinie BajracharyaRebecca M Nisbet
Sep 18, 2020·European Journal of Pharmacology·Miguel Vaz, Samuel Silvestre
Apr 14, 2021·Statistical Methods in Medical Research·Xubiao PengSteven S Plotkin
Jun 16, 2021·Wiener medizinische Wochenschrift·Sigrid Klotz, Ellen Gelpi
Jun 29, 2021·Journal of Alzheimer's Disease : JAD·Weina YaoUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Aug 8, 2021·International Journal of Molecular Sciences·John Tsu-An HsuFeng-Shiun Shie
Aug 12, 2021·Journal of Pharmacokinetics and Pharmacodynamics·Peter BloomingdaleNitin Mehrotra
Sep 18, 2021·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bruno P ImbimboClaudia Balducci

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
Circular dichroism
NMR
immunodepletion
phage display
ELISA
surface plasmon resonance
FRET
transfection
antisense oligonucleotide

Clinical Trials Mentioned

NCT02565511
NCT03531710
NCT03959553
NCT01850238
NCT02031198
NCT02579252
NCT02738450
NCT00998764
NCT00667810
NCT00996918

Software Mentioned

BLAST

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Journal of Neurochemistry
Abigail Herrmann, Tara Spires-Jones
Trends in Molecular Medicine
Jan Torleif Pedersen, Einar M Sigurdsson
© 2021 Meta ULC. All rights reserved